Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
This approach involves comprehensive molecular simulations of the catalytic and allosteric binding pockets and ensemble virtual screening that accounts for their conformational flexibility. In the case of designing modulators, the structural adjustments caused by reaction intermediates are considered to improve activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9BQ52
UPID:
RNZ2_HUMAN
Alternative names:
ElaC homolog protein 2; Heredity prostate cancer protein 2; Ribonuclease Z 2; tRNA 3 endonuclease 2; tRNase Z 2
Alternative UPACC:
Q9BQ52; B4DPL9; Q6IA94; Q9HAS8; Q9HAS9; Q9NVT1
Background:
Zinc phosphodiesterase ELAC protein 2, also known as Heredity prostate cancer protein 2, plays a crucial role in mitochondrial tRNA maturation. It is involved in removing a 3'-trailer from precursor tRNA, essential for RNA processing and ribosome assembly. This protein is associated with mitochondrial DNA complexes, initiating crucial cellular processes.
Therapeutic significance:
ELAC2 is linked to hereditary prostate cancer and combined oxidative phosphorylation deficiency 17, highlighting its importance in disease mechanisms. Understanding the role of ELAC2 could lead to novel therapeutic strategies for these conditions.